Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No worries tuna, thanks for checking it out...chart looks primed here for a big move
CHINA up .07 pre-market,, gonna run hard after 2.95
CHINA another bid UT !
CHINA bid UT, looking strong today, SLW , COIN and SCLN all up PM
symbol CHINA looking strong also pre-open, bid has UT'd. A break of 2.95 signals technical breakout and easy run into 3.00s
surprised SCLN not moving higher here
NMTI earnings news out
NMT Medical Announces Fourth-Quarter and Year-End 2009 Financial Results
Last update: 3/25/2010 7:30:15 AM
CLOSURE I Trial Data Analysis to Commence in Mid-April 2010;
BOSTON, Mar 25, 2010 (BUSINESS WIRE) -- --$5.8 Million Financing Closed in February will Fund Ongoing Clinical Trials and Development Programs
NMT Medical, Inc. (NMTI), an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced financial results for the quarter and fiscal year ended December 31, 2009.
Fourth-Quarter Results
Fourth-quarter 2009 total revenues were approximately $3.6 million compared with approximately $4.4 million for the quarter ended December 31, 2008.
Cardiac septal repair implant sales in North America for the fourth quarter of 2009 were approximately $2.1 million compared with approximately $3.0 million in the fourth quarter of 2008. Implant sales outside of North America were approximately $1.5 million in the fourth quarter of 2009 compared with $1.4 million in the corresponding period of 2008.
For the fourth quarter of 2009, NMT narrowed its net loss to approximately $1.9 million, or $0.15 per share, compared with a net loss of approximately $4.2 million, or $0.32 per share, for the corresponding period in 2008.
Full-Year Results
Total revenues for the twelve months ended December 31, 2009 were approximately $13.2 million compared with approximately $17.9 million for the same period in 2008.
Full-year 2009 cardiac septal repair implant sales in North America were approximately $9.1 million compared with approximately $11.7 million for the twelve-month period ended December 31, 2008. Implant sales outside of North America were approximately $4.1 million for the twelve-month period ended December 31, 2009 compared with approximately $6.1 million for the same period in 2008.
The net loss for the twelve months ended December 31, 2009 narrowed to approximately $12.4 million, or $0.94 per share, compared with a net loss of approximately $18.1 million, or $1.39 per share, for the corresponding period in 2008.
Management Comments
"We were pleased to achieve full-year revenues within our previously provided guidance range," said President and Chief Executive Officer Frank Martin. "Our strategy and efforts to increase unit sales of BioSTAR(R) in new territories outside of North America by entering and establishing distribution partnerships has resulted in BioSTAR(R) currently being available for commercial sale in 25 countries. In the fourth quarter, we began marketing our products in Brazil, Turkey and several countries in the Middle East. We are confident that NMT is well positioned to continue increasing its distribution outside of North America. As expected, tightly managed hospital inventory levels and the regulatory and product labeling requirements continue to limit our sales in North America."
"We believe 2010 is going to be a landmark year for NMT," said Martin. "We are approaching completion of CLOSURE I, our pivotal patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the United States. Data analysis is on schedule to commence in mid-April. Assuming positive results, we currently are targeting a third-quarter 2010 submission to the U.S. Food and Drug Administration for Pre-Market Approval of our STARFlex(R) device for the stroke and TIA indication. At that time, 100 percent of the randomized patient follow-up data will be available. In addition, we recently announced the formation of our Scientific Advisory Board, and that John E. Ahern, NMT's former Chairman and CEO, who had been actively involved with CLOSURE I since its inception, has stepped out of retirement to rejoin our Board of Directors."
Chief Operating Officer, Richard E. Davis, said, "The financial results of 2009 demonstrate that we have effectively managed our expenses as we narrowed our net loss and cash burn while expanding our worldwide distribution network. In 2009, we lowered our total operating costs by more than 25 percent over 2008. At the same time, we invested in and strengthened NMT's commercial infrastructure outside of North America. At December 31, 2009, cash and cash equivalents were approximately $8.9 million, which included two payments received in the fourth quarter related to settled patent infringement lawsuits -- a $2.75 million payment from W.L. Gore and the final payment of $250,000 from Cardia."
"In early 2010, we continued to strengthen our balance sheet with a $5.8 million financing through a private placement of common stock and warrants. In combination with the $4 million of availability under our current credit facility, we are confident that we have the financial resources necessary to support our ongoing clinical trials and development programs and fully execute our business plan. Pending results of the CLOSURE I trial, we currently anticipate full year 2010 revenues to increase modestly from 2009 levels," concluded Davis.
Conference Call Reminder
Management will conduct a conference call at 9:30 a.m. ET today to review the Company's financial results and provide a business update. Individuals who are interested in listening to the live webcast should log on to the "Investors" section of NMT Medical's website at . The conference call also may be accessed by dialing (877) 407-5790 or (201) 689-8328. For interested individuals unable to join the live conference call, a replay will be archived for one year via webcast on the Company's website.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 32,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.
Stroke is a leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and an additional 500,000 Americans experience a TIA.
For more information about NMT Medical, please visit .
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements -- including statements regarding the timing, cost, clinical status, and outcome of the Company's CLOSURE I trial, its ongoing clinical trials and development programs, the Company's expected savings from cost reductions, the Company's revenue expectations for 2010, the success of our new distribution partnerships, expansion of the Company's cardiovascular business and market opportunities, including stroke, TIA and any other new applications for the Company's technology or products, regulatory approvals for the Company's products in the United States and abroad and the Company's investment in product development -- involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may cause such a difference include, but are not limited to, the Company's ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading "Risk Factors" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, and subsequent filings with the U.S. Securities and Exchange Commission.
NMT Medical, Inc. and SubsidiariesConsolidated Statements of Operations For The Three Months Ended For The Twelve Months Ended December 31, December 31, 2009 2008 2009 2008 Revenues: Product sales $ 3,557,671 $ 4,437,954 $ 13,220,117 17,856,449 Net royalty income - - - 18,170 Total revenues 3,557,671 4,437,954 13,220,117 17,874,619 Costs and expenses: Cost of product sales 1,483,145 1,606,766 5,504,232 5,968,933 Research and development 2,286,961 3,573,096 8,923,462 13,194,376 General and administrative 1,268,651 1,589,532 6,763,779 8,578,640 Selling and marketing 1,374,693 1,917,974 5,466,823 8,783,784 Total cost and expenses 6,413,450 8,687,368 26,658,296 36,525,733 Net gain from settlement of litigation 950,500 - 950,500 - Loss from operations (1,905,279 ) (4,249,414 ) (12,487,679 ) (18,651,114 ) Other (expense) income: Currency transaction loss (15,518 ) (50,837 ) (1,554 ) (123,192 ) Interest income 1,047 105,287 89,366 767,724 Total other (expense) income (14,471 ) 54,450 87,812 644,532 Loss before income taxes (1,919,750 ) (4,194,964 ) (12,399,867 ) (18,006,582 ) Income tax expense 13,937 11,197 43,903 69,169 Net loss $ (1,933,687 ) $ (4,206,161 ) $ (12,443,770 ) $ (18,075,751 ) Basic & diluted loss per common share: $ (0.15 ) $ (0.32 ) $ (0.94 ) $ (1.39 ) Basic & diluted weighted average common shares outstanding: 13,228,294 13,082,391 13,189,137 13,019,653
NMT Medical, Inc. and SubsidiariesConsolidated Balance Sheets At December 31, At December 31, 2009 2008 Assets Current assets: Cash and cash equivalents $ 8,926,329 $ 4,899,179 Marketable securities - 12,674,639 Accounts receivable, net 1,683,829 2,511,934 Inventories 1,658,646 2,018,173 Prepaid expenses and other current assets 1,029,348 1,212,947 Total current assets 13,298,152 23,316,872 Property and equipment, net 694,520 928,693 $ 13,992,672 $ 24,245,565 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 5,017,863 $ 2,870,606 Accrued expenses 5,840,908 6,468,167 Total current liabilities 10,858,771 9,338,773 Long-term liabilities 554,143 507,426 Stockholders' equity: Preferred stock, $.001 par value Authorized--3,000,000 shares Issued and outstanding--none - - Common stock, $.001 par value Authorized--30,000,000 shares Issued and outstanding--13,268,294 and 13,122,391 shares in 2009 and 2008, respectively 13,268 13,122 Additional paid-in capital 53,175,464 52,659,855 Less treasury stock - 40,000 shares at cost (119,600 ) (119,600 ) Accumulated other comprehensive loss - (108,407 ) Accumulated deficit (50,489,374 ) (38,045,604 ) Total stockholders' equity 2,579,758 14,399,366 $ 13,992,672 $ 24,245,565
SOURCE: NMT Medical, Inc.
NMT Medical, Inc. Richard E. Davis, 617-737-0930 Chief Operating Officer red@nmtmedical.com
Copyright Business Wire 2010
ROHI, strong volume and gain yesterday, looking for follow through today, could run to $1 quick
CHINA bid UT
CHINA bid UT pre-market
ARDM news
Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that the last patient was enrolled and received the first dose in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.
“We have been very pleased with enrollment rates in this study and we are on track to have the results of this trial in the second half of 2010. The speed with which we enrolled these patients is indicative of the need they have for an effective and convenient treatment”
The randomized, double-blind, placebo-controlled ORBIT-2 (Once Daily Respiratory Bronchiectasis Inhalation Treatment) trial is being conducted in Australia and New Zealand. Following a 14 day screening period, the patients are being treated once-a-day for 28 days with either the active drug, or placebo, followed by a 28 day off-treatment period. This on-off sequence is repeated three times. The primary endpoint is defined as the mean change in Pseudomonas aeruginosa density in sputum (colony forming units – CFU - per gram) from baseline to day 28 of the active treatment group versus placebo. Safety and tolerability assessments of the treatment versus placebo group will be performed and secondary efficacy endpoints will include long term microbiological responses, time to an exacerbation, severity of exacerbations, length of time to resolve exacerbations, and changes in spirometry and in quality of life measurements.
The study will explore whether the novel formulation ARD-3150 has long term beneficial impacts on bronchiectasis – an orphan condition with currently no therapy specifically approved for its treatment.
The Company previously announced the initiation of the ORBIT-1 trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis under a U.S. IND, using another inhaled ciprofloxacin formulation (ARD-3100) that has a different drug release profile from ARD-3150. The results from each of these trials will produce an extensive data base of information from which to select the optimum product and the most appropriate endpoints to test in Phase 3.
“We have been very pleased with enrollment rates in this study and we are on track to have the results of this trial in the second half of 2010. The speed with which we enrolled these patients is indicative of the need they have for an effective and convenient treatment,” said Paul Bruinenberg, MD, Medical Director, Aradigm Corporation.
About bronchiectasis
Bronchiectasis (BE) is a chronic condition characterized by abnormal dilatation of the bronchi and bronchioles associated with chronic respiratory infections. It is frequently observed in patients with cystic fibrosis (CF). It is a condition, however, that affects about 110,000 people without CF in the United States and many more in other countries, and results from a cycle of inflammation, recurrent infection, and bronchial wall damage. There is currently no drug specifically approved for the treatment of this condition in the U.S.
About liposomal ciprofloxacin
Ciprofloxacin is a widely prescribed antibiotic to treat infections of the lung frequently experienced by CF and non-CF BE patients. It is often preferred because of its broad-spectrum anti-bacterial action. The available oral and intravenous formulations of ciprofloxacin are used to treat episodes of acute exacerbations of lung infections. The Company’s once-a-day, novel inhaled formulations of ciprofloxacin (ARD-3100 and ARD-3150) are being tested for chronic maintenance therapy as they are expected to achieve higher antibiotic concentration at the site of infection and relatively low systemic antibiotic concentrations to minimize side-effects. The Company previously reported positive results in Phase 2a studies of 22 CF patients and 36 BE patients who received ARD-3100 once-a-day for 2 (CF) or 4 (BE) weeks, respectively. The Company is also developing these formulations as a potential treatment for the prevention and treatment of bioterrorism infections, such as inhaled anthrax.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Forward-Looking Statements
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the timing and results of clinical trials, as well as the other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on March 24, 2010, and the Company’s Quarterly Reports on Form 10-Q.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.
Contacts
Aradigm Corporation
Nancy Pecota, Chief Financial Officer, 510-265-9370
I like CYTX as well as APPA, they are both dirt cheap here, after FDA news knocked them down a few pegs..
ROHI strong volume and move today, watch for gap up tomorrow and a move towards $1
do you only speak in caps lock until 4pmest?
who hasn't lost money here?...move on, noone presses the buy and sell button but them
then quit bitching
PNGXQ emerging from BK
DALLAS--(BUSINESS WIRE)--PNG Ventures, Inc. (OTCBB:PNGXQ - News) today announced it and its wholly owned subsidiaries, New Earth LNG, LLC, Arizona LNG, LLC, Applied LNG Technologies USA, LLC, Fleet Star, Inc., and Earth Leasing, Inc. (collectively, the “Company”), have successfully emerged from the voluntary reorganization filed on September 9, 2009 under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Plan of Reorganization, confirmed on March 12, 2010 resulted in conversion of a majority of the Company’s outstanding debt to new common equity, and eliminated or mitigated the impact of certain onerous contracts inherited as part of the Company’s June 30, 2008 Share Exchange Transaction with Earth Biofuels, Inc.
Throughout the reorganization process, the Company operated its business in the ordinary course. The Company’s day-to-day operations and delivery of products or services to its customers were not adversely affected by the Chapter 11 filing.
Cem Hacioglu, President & CEO of PNG Ventures, said, “We are very happy to have successfully completed this critical process within a short period and are excited about the prospects of our new company going forward. Having recapitalized our balance sheet and eliminated a number of debilitating operational and financial impediments, we are now superbly positioned to take advantage of the tremendous growth opportunities in the alternative fuels market and become the preeminent provider of cleaner burning fuels for the domestic and international markets.”
Mr. Hacioglu continued, “On behalf of our Board of Directors and management team, we would like to thank our employees and professional team for their hard work, perseverance and dedication. We would also like to thank our Plan sponsors, Medley Capital and Sandell Asset Management for their faith in us and our long-term prospects. Most especially, however, we would like to thank our customers, suppliers and other business partners for their patience throughout this arduous process. We will continue to work very hard to be deserving of the trust and confidence they have placed in us and our Company.”
As part of the Plan of Reorganization, the majority of the Company’s senior credit facility was converted into approximately 66% of the common stock of the newly organized Company with the balance settled for a combination of cash and a $9.8 million four-year term loan. In addition, the Company’s trade and unsecured debts were exchanged for a creditor trust of approximately $1.2 million and 7.5% of the common stock of the newly reorganized Company. The Plan was funded by approximately $8.3 mm in return for a combination of approximately 26.5% of the common stock of the newly reorganized Company, a new $5.5 million four-year term loan and $250,000 short-term loan. Previously outstanding equity, including all options, warrants and other derivative instruments linked to that equity, was eliminated as part of the Plan. The Company remains a public entity and, upon completion of the customary regulatory review and distribution of the creditor shares, should resume trading under a new symbol based on the name Applied Natural Gas Fuels, Inc.
The foregoing is intended as a summary of the terms of the final Plan of Reorganization and confirmation process. A more detailed description can be found within the Company’s Current Report on Form 8-K which will be filed with the Securities and Exchange Commission. A copy of the Plan and Disclosure Statement are available at www.altlng.com.
About Applied Natural Gas Fuels, Inc. (formerly known as “PNG Ventures, Inc.”)
Through its Applied LNG Technologies and other subsidiaries, the Company engages in the production, distribution, and sale of liquefied natural gas (“LNG”) to customers consisting of public utilities, industrial end-users and other fleet customers within the transportation, manufacturing, distribution, and municipal markets, primarily in California, Arizona, and Nevada. The Company also offers turnkey fuel solutions, including delivery, equipment storage, fuel dispensing equipment, and fuel loading facilities.
Forward-Looking Statements Disclosure
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” “will,” and other terms with similar meaning. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can provide no assurances that these assumptions will prove to be correct. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: the ability of the Company to successfully implement its Plan of Reorganization as confirmed; the Company’s ability to implement its business model as it has now emerged from bankruptcy protection; the Company’s ability to maintain its operations as a going concern and to service the newly restructured indebtedness it has incurred under its Plan of Reorganization; the Company’s ability to obtain and maintain normal terms with vendors, service providers, and leaseholders now that it has emerged from bankruptcy proceedings; the ability of the Company to fund and execute its business plan; the ability of the Company to attract, motivate and/or retain key executives and associates; the ability of the Company to attract and retain customers; and statements or assumption underlying the Company’s Plan of Reorganization and any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission and other filings with the SEC. Similarly, these and other factors, including the terms and impact of the Plan of Reorganization, as confirmed, can affect the value of the Company’s equity securities. No assurances can be provided as to when, if at all, the Company’s new securities may be listed on a national securities exchange or on the over-the-counter market, or as to when, if at all, a trading market may be developed in the Company’s securities. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this press release. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. We assume no duty to update or revise our forward-looking statements based on changes in internal estimates, expectations, or otherwise or to reflect events or circumstances after the date hereof.
Contact:
PNG Ventures, Inc.
Rachel Croft, 214-613-0214
info@altlng.com
See, gonzilee's problem, other than not knowing how to shut the caps lock off, is that he is always buying into the hype on frontloaded POS stocks on here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46573761
CHINA up nice today, looking for a follow through, and a break of 2.95
News out on earnings...The Wholesale - Medical Equipment industry in which Rotech Healthcare is a member generated a Revenue increase of 7.08% over its most recent three months which compared to a decrease of -4.5% in Revenue for the company over the earlier or comparable three months.
T12-NEWS reports that the Revenue of Rotech Healthcare for its 3 months ended December 31, 2009 Decreased by -4.5%
03/24/2010
New York, NY, March 24, 2010,T12-NEWS reports that Fourth Quarter Revenue for Rotech Healthcare (OTC:ROHI) for its three months ended December 31, 2009 was $123,187,000, a -4.5% decrease over the year earlier three months when Rotech Healthcare generated $128,985,000 in Revenue. The fourth quarter numbers compared to a -11.88% decrease in Revenue for its most recent twelve months ended December 31, 2009.
The Wholesale - Medical Equipment industry in which Rotech Healthcare is a member generated a Revenue increase of 7.08% over its most recent three months which compared to a decrease of -4.5% in Revenue for the company over the earlier or comparable three months. The industry's Revenue statistics compared to a decrease in aggregate Revenue of -13.26% for the S&P 500's non financial companies and an aggregate decrease in Revenue of -17.12% for the Dow Jones Industrial's non financial companies over their most recent three months.
The Wholesale - Medical Equipment industry is currently ranked at 28 out of 230 industries based on Revenue growth rates for all industries over the latest 12 months according to T12-NEWS.
T12-NEWS is a publisher of proprietary financial news. It is dedicated to reporting on revenue and earnings data, which cover a public company’s most recent versus previous or TRAILING 12 month and fourth quarter financial information and data. The proprietary news that it publishes is calculated from the quarterly reports (10Q’s) and annual reports (10K’s) which a publicly traded company is required to file with the United States Securities Exchange Commission (SEC). The reporting of trailing 12 month news for public companies is essential because public companies are not required by the U.S. Securities & Exchange Commission (SEC) to report trailing 12 month or fourth quarter financial data when they make their quarterly and annual filings.
The reporting and publishing of Trailing 12 month data is necessary because a constant look back at the previous 12 months of comparative data will give investors a more stable reading on the true health of a public company. T12-NEWS also covers and reports on fourth quarter revenue for all publicly traded companies. Fourth quarter comparisons of financial information as compared to previous fiscal year fourth quarters can also give investors better readings on the financial health of a publicly traded company. Public companies can withhold or push negative information from the first three quarters of a fiscal year to their fourth quarter because they are not required to file a quarterly report for their fourth quarter by the SEC. The quarterly, semi-annual, nine month and annual reports that a public company is required to be filed with the SEC can be skewed because they cover shorter time horizons.
T12-NEWS publishes news on revenue and earnings or Net Income on thousands of public companies, which trade on U.S. Securities Exchanges. Access to all current and archived trailing twelve month and fourth quarter news and reports that are published by T12-NEWS are available at www.StockTrendNews.com.
Copyright 2010 StockTrendNews.com
Looks cleared for dollar land tomorrow
ROHI earnings out too !!
T12-NEWS reports that the Revenue of Rotech Healthcare for its 3 months ended December 31, 2009 Decreased by -4.5%
03/24/2010
New York, NY, March 24, 2010,T12-NEWS reports that Fourth Quarter Revenue for Rotech Healthcare (OTC:ROHI) for its three months ended December 31, 2009 was $123,187,000, a -4.5% decrease over the year earlier three months when Rotech Healthcare generated $128,985,000 in Revenue. The fourth quarter numbers compared to a -11.88% decrease in Revenue for its most recent twelve months ended December 31, 2009.
The Wholesale - Medical Equipment industry in which Rotech Healthcare is a member generated a Revenue increase of 7.08% over its most recent three months which compared to a decrease of -4.5% in Revenue for the company over the earlier or comparable three months. The industry's Revenue statistics compared to a decrease in aggregate Revenue of -13.26% for the S&P 500's non financial companies and an aggregate decrease in Revenue of -17.12% for the Dow Jones Industrial's non financial companies over their most recent three months.
The Wholesale - Medical Equipment industry is currently ranked at 28 out of 230 industries based on Revenue growth rates for all industries over the latest 12 months according to T12-NEWS.
T12-NEWS is a publisher of proprietary financial news. It is dedicated to reporting on revenue and earnings data, which cover a public company’s most recent versus previous or TRAILING 12 month and fourth quarter financial information and data. The proprietary news that it publishes is calculated from the quarterly reports (10Q’s) and annual reports (10K’s) which a publicly traded company is required to file with the United States Securities Exchange Commission (SEC). The reporting of trailing 12 month news for public companies is essential because public companies are not required by the U.S. Securities & Exchange Commission (SEC) to report trailing 12 month or fourth quarter financial data when they make their quarterly and annual filings.
The reporting and publishing of Trailing 12 month data is necessary because a constant look back at the previous 12 months of comparative data will give investors a more stable reading on the true health of a public company. T12-NEWS also covers and reports on fourth quarter revenue for all publicly traded companies. Fourth quarter comparisons of financial information as compared to previous fiscal year fourth quarters can also give investors better readings on the financial health of a publicly traded company. Public companies can withhold or push negative information from the first three quarters of a fiscal year to their fourth quarter because they are not required to file a quarterly report for their fourth quarter by the SEC. The quarterly, semi-annual, nine month and annual reports that a public company is required to be filed with the SEC can be skewed because they cover shorter time horizons.
T12-NEWS publishes news on revenue and earnings or Net Income on thousands of public companies, which trade on U.S. Securities Exchanges. Access to all current and archived trailing twelve month and fourth quarter news and reports that are published by T12-NEWS are available at www.StockTrendNews.com.
Copyright 2010 StockTrendNews.com
ROHI .61 break, and it's clear to run to .70s, sorry it doesn;t have enough zeroes in front of it tho
ROHI up nice, handed it out at .50, closed at .594
ROHI ask getting absolutely pounded here, just 25 million OS
ROHI info
Rotech Healthcare Inc.
2600 Technology Drive
Suite 300
Orlando, FL 32804
http://www.rotech.com
* Phone: (407) 822-4600
*
OTC Market Tier
Pink Quote/OTCBB
*
Primary SIC — Industry Classification
8082 - Home health care services
*
State Of Incorporation
DE
*
Jurisdiction Of Incorporation
United States
*
Company Officers
Philip L. Carter, President, CEO
Michael R. Dobbs, COO
Steve Alsene, CFO
*
SEC Reporting Status
SEC Reporting Company
*
CIK
0001175108
*
Fiscal Year End
12/31
*
Estimated Market Cap
$11,732,424 as of Mar 23, 2010
*
Outstanding Shares
25,505,270 as of May 5, 2008
*
Number of Shareholders of Record
95 as of Mar 7, 2008
good grief, i think he needs to change his maxi pad
HERE HERE !!!!!
ROHI about to explode here .46 x .50
ILNS bid UT .10 x .11.....ultra thin
I see gonzo put the caps lock back on.
ROHI, bids stacking here, could run anytime
ROHI up .04, solid volume, low floater....thin to .60
CHINA solid chart play, breaks 2.95 it's cleared
ILNS NEWS !!!
Intellect Neurosciences, Inc. Announces CEO to Deliver Key Note Speech on Alzheimer's Monoclonal Antibodies at International Conference in Beijing
Last update: 3/24/2010 5:30:00 AM
NEW YORK, March 24, 2010 /PRNewswire via COMTEX/ -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that its Chairman & Chief Executive Officer, Daniel Chain, PhD, will deliver the key note speech at a session entitled "Alzheimer's Monoclonal Antibodies" at the BIT Life Sciences 2nd International Conference on Monoclonal Antibodies. The conference, known as ICA-2010 (), is being held March 24 - 26 in Beijing, China. Dr. Chain's speech, "Promise and Challenges of Developing Safe and Effective Therapeutic Antibodies for Alzheimer's Disease", will provide an overview and realistic assessment of the road ahead for Alzheimer's antibody-based treatments.
"We are gratified to see how the approach we conceived several years ago is being used by major pharmaceutical companies developing drugs to combat Alzheimer's disease, as Alzheimer's patients need strong and capable partners," Dr. Chain said. "We believe that several therapeutic agents may be necessary to fully treat the AD population, and that our licensing efforts and our internal development programs will increase the likelihood of developing safe, effective therapies."
Dr. Chain is the inventor of the Company's ANTISENILIN(R) antibody technology, for which patents have been granted in Europe, Japan, China and elsewhere. Patent applications are pending in the United States. Intellect granted a royalty-bearing license to Wyeth and Elan International Ltd. in 2008, the developers of Bapineuzumab, a monoclonal antibody product in Phase 3 clinical trials. Elan, through an affiliate, assigned the license to Janssen AI, a subsidiary of Johnson and Johnson, in 2009. Intellect entered into a second royalty-bearing license agreement with an undisclosed top tier global pharmaceutical company in January 2009, and granted an option to purchase a license to GlaxoSmithKline in April 2009.
A report in the medical journal Lancet Neurology, Volume 9, Issue 4, Pages 363 - 372, April 2010, indicates that Alzheimer's patients receiving Bapineuzumab show a significant reduction in amyloid plaques in the brain.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits, known as beta-amyloid, on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are more than 5 million Americans and about 30 million people suffering from Alzheimer's disease world wide, with the number expected to increase dramatically as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate more than US $6 billion in sales by 2010, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The Company's drug product pipeline includes OX1 which has been tested in Phase 1 clinical trials; IN-N01, a humanized monoclonal antibody designed to promote the clearance of soluble beta amyloid; and RECALL-VAX, a vaccine technology that has potential to delay or prevent Alzheimer's disease in people who are at risk. The Company has underlying intellectual property assets, including several patent families supporting its internal programs, and a pivotal patent estate regarding passive AD immunotherapy. The Company granted a non-exclusive, worldwide, royalty-bearing license to its ANTISENILIN(R) monoclonal antibody platform to Wyeth and Elan Pharma International Ltd. The license grants rights to Wyeth and Elan under Intellect's patents with respect to the development and sale of Bapineuzumab, a monoclonal antibody intended to treat AD. Wyeth and Elan are currently testing Bapineuzumab in several thousand Alzheimer's patients in a Phase 3 clinical trial. The Company granted a similar non-exclusive license to another top tier global pharmaceutical company and granted an option to purchase a license to GlaxoSmithKline.
For additional information, please visit .
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K, (file no. 333-128226) filed on October 13, 2009, and Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2009, filed on February 16, 2010.
SOURCE Intellect Neurosciences, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
COIN up .035 PM
APCVZ up PM
MF holding strong after announcing Corzine to company
IDTI, no trades since favorable ruling against LSI